The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

i am a healthcare professional i am not a healthcare professional
JANUMET® (sitagliptin/metformin HCl) tablets

Selected Important Risk Information
Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin. Therefore, in patients in whom any such study is planned, JANUMET should be temporarily discontinued at the time of or before the procedure, withheld for 48 hours subsequent to the procedure, and reinstituted only after renal function has been re-evaluated and found to be normal.

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUMET or any other antidiabetic drug.

Please read the Boxed Warning about lactic acidosis.